Dekker R J, Eichinger A, Stoop A A, Bode W, Pannekoek H, Horrevoets A J
Department of Biochemistry Academic Medical Center, University of Amsterdam, Amsterdam, 1105 AZ, The Netherlands.
J Mol Biol. 1999 Oct 29;293(3):613-27. doi: 10.1006/jmbi.1999.3178.
Substitution of the native variable region-1 (VR1/37-loop) of thrombin by the corresponding VR1 of tissue-type plasminogen activator (thrombin-VR1(tPA)) increases the rate of inhibition by plasminogen activator inhibitor type 1 (PAI-1) by three orders of magnitude, and is thus sufficient to confer PAI-1 specificity to a heterologous serine protease. A structural and kinetical approach to establish the function of the VR1 loop of t-PA in the context of the thrombin-VR1(tPA) variant is described. The crystal structure of thrombin-VR1(tPA) was resolved and showed a conserved overall alpha-thrombin structure, but a partially disordered VR1 loop as also reported for t-PA. The contribution of a prominent charge substitution close to the active site was studied using charge neutralization variants thrombin-E39Q(c39) and thrombin-VR1(tPA)-R304Q(c39), resulting in only fourfold changes in the PAI-1 inhibition rate. Surface plasmon resonance revealed that the affinity of initial reversible complex formation between PAI-1 and catalytically inactive Ser195-->Ala variants of thrombin and thrombin-VR1(tPA) is only increased fivefold, i.e. KD is 652 and 128 nM for thrombin-S195A and thrombin-S195A-VR1(tPA), respectively. We established that the partition ratio of the suicide substrate reaction between the proteases and PAI-1 was largely unaffected in any variant studied. Hirugen allosterically decreases the rate of thrombin inhibition by PAI-1 2.5-fold and of thrombin-VR1(tPA) 20-fold, by interfering with a unimolecular step in the reaction, not by decreasing initial complex formation or by altering the stoichiometry. Finally, kinetic modeling demonstrated that acylation is the rate-limiting step in thrombin inhibition by PAI-1 (k approximately 10(-3) s(-1)) and this kinetic block is alleviated by the introduction of the tPA-VR1 into thrombin (k>1 s(-1)). We propose that the length, flexibility and different charge architecture of the VR1 loop of t-PA invoke an induced fit of the reactive center loop of PAI-1, thereby enhancing the rate of acylation in the Michaelis complex between thrombin-VR1(t-PA) and PAI-1 by more than two orders of magnitude.
用组织型纤溶酶原激活剂的相应可变区 1(VR1/37 环)(凝血酶 -VR1(tPA))替代凝血酶的天然可变区 1,可使 1 型纤溶酶原激活剂抑制剂(PAI -1)的抑制速率提高三个数量级,因此足以赋予异源丝氨酸蛋白酶 PAI -1 特异性。本文描述了一种在凝血酶 -VR1(tPA)变体背景下建立 t -PA 的 VR1 环功能的结构和动力学方法。解析了凝血酶 -VR1(tPA)的晶体结构,其显示出与α-凝血酶整体结构保守,但 VR1 环部分无序,这与 t -PA 的情况一致。使用电荷中和变体凝血酶 -E39Q(c39)和凝血酶 -VR1(tPA)-R304Q(c39)研究了靠近活性位点的显著电荷替代的作用,结果 PAI -1 抑制速率仅变化四倍。表面等离子体共振显示,PAI -1 与凝血酶和凝血酶 -VR1(tPA)的催化失活 Ser195→Ala 变体之间初始可逆复合物形成的亲和力仅增加五倍,即凝血酶 -S195A 和凝血酶 -S195A -VR1(tPA)的 KD 分别为 652 和 128 nM。我们确定,在所研究的任何变体中,蛋白酶与 PAI -1 之间自杀底物反应的分配比基本不受影响。水蛭素通过干扰反应中的单分子步骤,而非通过降低初始复合物形成或改变化学计量,变构降低 PAI -1 对凝血酶的抑制速率 2.5 倍以及对凝血酶 -VR1(tPA)的抑制速率 20 倍。最后,动力学建模表明,酰化是 PAI -1 抑制凝血酶的限速步骤(k 约为 10^(-3) s^(-1)),而将 tPA -VR1 引入凝血酶可缓解此动力学障碍(k>1 s^(-1))。我们提出,t -PA 的 VR1 环的长度、柔韧性和不同的电荷结构引发了 PAI -1 反应中心环的诱导契合,从而使凝血酶 -VR1(t -PA)与 PAI -1 之间米氏复合物中的酰化速率提高了两个多数量级。